RefleXion Expands Medicare Reimbursement for SCINTIX Therapy Across Majority of U.S. Regions
RefleXion Medical has announced a significant advancement in expanding access to its innovative SCINTIX® autonomous radiotherapy, as another Medicare Administrative Contractor (MAC), Noridian Healthcare Solutions, LLC, has approved favorable reimbursement rates for the therapy. This latest decision marks a crucial step toward improving patient access to cutting-edge cancer treatments, particularly in freestanding centers (FSCs), which serve a substantial portion of oncology patients across the United States.
The decision by Noridian builds upon earlier approvals from other MACs and collectively extends reimbursement coverage to more than half of U.S. states and territories. This development is expected to accelerate the adoption of SCINTIX therapy and reduce financial barriers that have traditionally limited access to advanced radiotherapy solutions.
Understanding the Role of Medicare Administrative Contractors
Medicare Administrative Contractors (MACs) play a vital role in the U.S. healthcare system by determining reimbursement policies for services provided to Medicare beneficiaries. Their decisions directly influence whether healthcare providers can offer certain treatments in a financially sustainable manner.
Noridian Healthcare Solutions is one of the key MACs responsible for processing Medicare claims and setting payment policies across multiple jurisdictions. Its recent decision to establish reimbursement rates for SCINTIX therapy signals growing institutional recognition of the therapy’s clinical and economic value.
This move follows similar decisions by two other MACs that had already approved enhanced reimbursement levels in three jurisdictions covering southern and eastern regions of the United States. Together, these decisions represent a strong and coordinated shift toward supporting innovation in cancer care.
Expansion of Coverage Across States and Territories
Noridian’s decision significantly broadens the geographic reach of SCINTIX therapy by extending reimbursement to an additional 16 states and U.S. territories. These include:
- Alaska
- Arizona
- California
- Hawaii
- Idaho
- Montana
- Nevada
- North Dakota
- Oregon
- South Dakota
- Utah
- Washington
- Wyoming
- American Samoa
- Guam
- Northern Mariana Islands
With this expansion, Medicare beneficiaries in these regions can now access SCINTIX therapy in freestanding centers with reduced financial burden. Importantly, this brings coverage to a diverse mix of urban, rural, and remote areas, helping address disparities in cancer treatment availability.
Importance of Freestanding Centers in Cancer Care
Freestanding centers play a critical role in delivering radiation therapy in the United States. More than 40 percent of cancer patients receiving radiation treatments are treated in these facilities rather than hospital-based settings.
These centers are often more accessible to patients, especially those living in suburban or rural areas. They also tend to provide more personalized care and shorter wait times. However, adoption of advanced therapies in FSCs has historically been limited by reimbursement challenges.
By establishing payment rates that reflect the true cost of delivering SCINTIX therapy, Noridian’s decision helps ensure that freestanding centers can sustainably offer this innovative treatment. This is expected to drive broader adoption and improve patient outcomes.
SCINTIX Therapy: A Breakthrough in Radiotherapy
SCINTIX therapy represents a new frontier in cancer treatment, combining advanced imaging and targeted radiation delivery. Unlike conventional radiotherapy, which often targets tumors based on static imaging, SCINTIX uses real-time biological signals to guide treatment.
A key component of SCINTIX therapy is its ability to track and treat multiple tumors simultaneously, making it particularly valuable for patients with metastatic cancer. This approach has the potential to improve precision, reduce damage to healthy tissues, and enhance overall treatment effectiveness.
The Functional Modeling Process
One of the defining features of SCINTIX therapy is its unique pre-treatment procedure known as functional modeling. This step involves analyzing the biological activity of tumors using advanced imaging techniques.
Functional modeling allows clinicians to map out how tumors behave in real time, enabling highly personalized treatment planning. Following this process, patients typically undergo up to five treatment sessions, during which radiation is delivered with exceptional precision.
Noridian’s reimbursement decision includes payment for both the technical and professional components of this process. This is particularly important because functional modeling requires additional physician expertise and time, making it more resource-intensive than traditional planning methods.
Comprehensive Reimbursement Structure
The reimbursement framework established by Noridian covers several critical aspects of SCINTIX therapy:
- Technical components of the functional modeling procedure
- Technical components of the treatment sessions
- Professional component for physician involvement in functional modeling
Additionally, the professional payment component is applicable not only in freestanding centers but also in hospital outpatient departments within Noridian’s jurisdictions. This ensures consistency in reimbursement across different care settings and further supports widespread adoption.
By recognizing the complexity and value of SCINTIX therapy, this reimbursement structure aligns financial incentives with clinical innovation.
Impact on Patients and Providers
The expanded reimbursement is expected to have a profound impact on both patients and healthcare providers.
For Patients:
- Improved access to advanced cancer treatment options
- Reduced out-of-pocket costs
- Availability of cutting-edge care closer to home
- Potential for better treatment outcomes
For Providers:
- Increased confidence in adopting SCINTIX technology
- Financial sustainability for offering advanced therapies
- Ability to remain competitive in an evolving healthcare landscape
Todd Powell, President and CEO of RefleXion Medical, emphasized the importance of this development, noting that it removes a significant barrier to patient access while providing reassurance to providers aiming to incorporate innovative treatments.
Driving Innovation in Oncology Care
The decisions by Noridian and other MACs reflect a broader trend in healthcare toward supporting value-based innovation. As new technologies emerge, reimbursement policies must evolve to ensure that patients can benefit from advancements without undue financial strain.
SCINTIX therapy exemplifies the kind of innovation that has the potential to transform cancer care. By enabling more precise and adaptive treatment, it addresses some of the longstanding limitations of traditional radiotherapy.
The growing support from Medicare contractors suggests increasing confidence in the clinical and economic benefits of such technologies.
Looking Ahead: The Future of SCINTIX Therapy
With reimbursement now established across a majority of U.S. regions, SCINTIX therapy is poised for significant growth. RefleXion Medical is likely to continue working with additional MACs and private payers to further expand coverage.
As adoption increases, more clinical data will become available, potentially reinforcing the therapy’s value and leading to even broader acceptance. This could pave the way for SCINTIX to become a standard option in the treatment of certain cancers.
Moreover, the success of SCINTIX may encourage further investment in similar technologies, driving continued innovation in the field of oncology.
The expansion of Medicare reimbursement for SCINTIX therapy by Noridian Healthcare Solutions marks a major milestone in improving access to advanced cancer treatments. By covering additional states and territories and supporting freestanding centers, this decision helps ensure that more patients can benefit from cutting-edge care.
As healthcare systems increasingly prioritize innovation and patient-centered solutions, developments like this highlight the importance of aligning reimbursement policies with technological progress. For patients, providers, and the broader medical community, the future of cancer treatment looks increasingly promising.
About RefleXion Medical
RefleXion is a privately held external-beam theranostic oncology company located in Hayward, Calif. It is the first and only company commercializing SCINTIX autonomous radiotherapy, an innovative technology that uses a single radiotracer injection to turn cancer cells into real-time biological beacons to guide treatment delivery. SCINTIX therapy is FDA-cleared for FDG-guided treatment of lung and bone tumors, including metastases. The RefleXion X2 platform is also cleared for conventional image-guided radiotherapy for solid tumors throughout the body
